DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

Market Cap	130.75B -12.7%
Revenue (ttm)	242.69B -2.6%
Net Income	50.27B +2,369.7%
EPS	1,791.00 +2,288.0%
Shares Out	27.04M
PE Ratio	2.70
Forward PE	n/a
Dividend	120.00 (2.42%)
Ex-Dividend Date	Dec 29, 2025

Volume	203,379
Average Volume	105,990
Open	4,980.00
Previous Close	4,990.00
Day's Range	4,835.00 - 4,980.00
52-Week Range	4,745.00 - 6,390.00
Beta	0.47
RSI	39.88
Earnings Date	May 14, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 404
• Stock Exchange: KOSDAQ
• Ticker Symbol: 006620

Financial Performance

In 2025, DongKoo Bio & Pharma's revenue was 242.69 billion, a decrease of -2.64% compared to the previous year's 249.27 billion. Earnings were 50.27 billion, an increase of 2369.74%.